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The purpose of this study was to determine the optimal timing of intravenous glucagon infusion 
for the treatment of acute occlusive mesenteric &hernia. The superior mesenteric artery (SMA) was 
occluded for 85 min in 106 Sprague-Dawley anesthetized rats. The animals were divided into 12 
treatment groups according to the timing of glucagon and saline administration, and survival was 
measured to 48 hr. Without treatment, all rats died within 24 hr. Intravenous saline (10 ml/kg/hr) for 
2 hr did not significantly improve 48-hr survival (17-3396). Glucagon (1.6 pglkglmin iv) plus saline 
(10 ml/kg/hr iv) for 2 hr after SMA occlusion significantly improved survival from 33% (saline 
control) to 83% (P < 0.02). The same treatment begun 1 hr before SMA release (during ischemia) did 
not significantly improve survival (33% at 48 hr). Glucagon infusion during occlusive mesenteric 
&hernia was detrimental when added to effective post&hernia treatment, reducing survival from 83 
to 33% (P < 0.02). Adequate saline infusion was required for glucagon efficacy after ischemia, as 
shown by an intermediate 48-hr survival of 50% when only maintenance saline (1.5 ml/kg/hr) was 
given. These data suggest that glucagon therapy should be delayed until after operative release of 
an acute SMA occlusion and should be accompanied by vigorous volume expansion. Q 1985 Academic 
INTRODUCTION 
Acute mesenteric &hernia due to embo- 
lism or thrombosis is associated with high 
mortality [ 151. To improve the outcome of 
these patients, selective mesenteric vasodilator 
therapy has been advocated as an adjunct to 
standard surgical treatment [ 1, 31. Glucagon 
is a potent mesenteric vasodilator that has 
been shown to effectively increase normal 
superior mesenteric artery @MA) blood flow 
even when administered intravenously [7, 8, 
141. Using a rat SMA ischemia model, Kaz- 
mers et al. demonstrated prolonged survival 
after intravenous glucagon given both during 
and after the ischemic period [9]. In a canine 
model of occlusive mesenteric ischemia, 
however, we demonstrated that glucagon did 
’ To whom correspondence and reprint requests should 
be addressed: Department of Surgery, Dartmouth-Hitch- 
cock Medical Center, 2 Maynard Street, Hanover, NH 
03756. 
not improve ileal blood flow until after release 
of tourniquet ischemia, and, in fact, was 
detrimental during ischemia [ 161. Based on 
these studies, we hypothesized that the ben- 
eficial effects of glucagon treatment might be 
due primarily to relief of mesenteric vasocon- 
striction that occurs after intestinal ischemia, 
rather than to beneficial effects during SMA 
occlusion. The present study was designed to 
test this hypothesis by examining the survival 
of rats after intravenous glucagon therapy 
given at various times in relation to occlusive 
mesenteric &hernia. 
METHODS 
Male Sprague-Dawley rats weighing 400 
+ 12 g (mean + 1 SD, range: 370-430 g) 
that had been allowed free access to food 
and water were anesthetized with chloral 
hydrate (0.5 g/kg ip). Using clean surgical 
technique, one jugular vein was cannulated 
with PE 50 tubing to allow subsequent intra- 
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Ftc. 1. Experimental protocol illustrating the 12 treat- 
ment groups and their 48-hr survival. Significant differ- 
ences are indicated from other groups (x2). 
venous infusion. A midline laparotomy was 
performed, and the cranial mesenteric artery 
(SMA) was exposed at its origin from the 
aorta. Mesenteric &hernia was then produced 
by 85 min of SMA occlusion using a micro- 
serrefine vascular clamp applied at the SMA 
origin. After clamp removal, intestinal reper- 
fusion occurred, as evidenced by rapid return 
of color and arterial pulsation in the mesen- 
tery. The 85-min duration of ischemia was 
selected after pilot studies in our laboratory 
demonstrated that this was the minimum 
time required to produce 100% mortality at 
48 hr with no treatment. During the time of 
SMA occlusion, the abdomen was temporar- 
ily reapproximated to prevent evaporative 
fluid loss and intestinal desiccation. Following 
the ischemic period and a subsequent 2-hr 
treatment interval, the jugular vein catheter 
was removed and the cervical and abdominal 
incisions closed with silk suture. The animals 
were then observed at 4, 8, 16, 24, and 48 
hr, and their survival noted. Previous data 
and pilot studies from our laboratory dem- 
onstrated that all rats surviving 48 hr after 
intestinal ischemia had prolonged survival 
[9]. Therefore, 48-hr survival was judged 
sufficient to predict long-term survival in this 
study. Selected animals underwent autopsy 
with light microscopic examination of their 
small intestine. 
Rats received either no treatment, intra- 
venous normal saline in varying dosage, or 
intravenous normal saline plus glucagon, at 
varying times with respect to intestinal isch- 
emia (Fig. I). Nominal intravenous infusion 
rates were based on an expected weight of 
400 g for all rats. Glucagon was given at 1.60 
+ .05 pg/kg/min (mean + 1 SD), with a range 
of 1.49 to 1.7 1 pg/kg/min due to individual 
rat weight variations. Normal saline was in- 
fused at 10.2 -t 0.9 ml/kg/hr (mean -t 1 SD), 
with a range of 9.3 to 14.0 ml/kg/hr in 
individual rats. Among the 12 treatment 
groups, the range of mean rat weight, gluca- 
gon dose, and saline dose was 392 to 405 g, 
1.50 to 1.60 pg/kg/min and 9.9 to 10.1 ml/ 
kg/hr, respectively. 
A total of 106 rats were divided into the 








No treatment (n = 6) 
Normal saline for 60 min before and 60 min after SMA declamping (n = 6) 
Glucagon in saline for 60 min before, and saline alone for 60 min after 
SMA declamping (n = 6) 
Saline for 60 min before, and glucagon in saline for 60 min after SMA 
declamping (n = 6) 
Glucagon in saline both 60 min before and after SMA declamping (n = 12) 
Saline for 60 mm beginning 35 min before SMA clamping, followed by 
glucagon in saline for 60 min before and 60 min after SMA declamping 
(n = 6) 
Saline at 20 ml/kg/hr (2X normal dose) beginning 35 min before SMA 
clamping, followed by glucagon in saline for 60 min before and 60 min 
after SMA declamping (n = 6) 
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Group 8 Saline alone for 120 min after SMA declamping (n = 6) 
Group 9 Glucagon in saline for 120 min after SMA declamping (n = 12) 
Group 10 Glucagon in 1.5 ml/kg/hr saline (l/6 normal dose) for 120 min after SMA 
Group 1 
Group 1 
declamping (n = 16) 
1 Saline for 60 min before, and glucagon in saline for 120 min after SMA 
declamping (n = 12) 
2 Glucagon in saline for 60 min before and 120 min after SMA declamping 
(n = 12) 
Data were computerized and life table 
survival (Kaplan-Meier product-limit) was 
compared among groups with the Mantel- 
Cox nonparametric test, as well as by x2 
analysis at the 48hr time point [5]. 
RESULTS 
Survival at 48 hr for the 12 treatment 
groups is summarized in Fig. 1. Without 
treatment, 85 min of SMA occlusion was 
100% fatal, with O/6 rats surviving 24 hr 
(Group 1). Vigorous saline replacement (10 
ml/kg/hr), given 1 hr before and 1 hr after 
SMA declamping, did not statistically im- 
prove survival, with l/6 rats surviving 48 hr 
(17%, Group 2, Fig. 2). The addition of 
intravenous glucagon at 1.6 pg/kg/min to 
this saline treatment for 1 hr before SMA 
declamping also did not significantly improve 
survival, with 2/6 rats surviving 48 hr (33%, 
Group 3). Delaying this I-hr glucagon infu- 
sion until after mesenteric ischemia resulted 
in the same 33% survival at 48 hr (2/6 rats, 
Group 4). Although early survival (up to 24 
48 
TIME IHOURS) 
FIG. 2. Saline treatment (10 ml/kg/hr) during and 
after mesenteric &hernia (G-2) did not significantly 
improve survival compared with no treatment (G-l). 
hr) appeared to be somewhat improved by 
this delay in treatment (Fig. 3), overall life 
table survival was not statistically different. 
Increasing the duration of glucagon infusion 
to 2 hr (1 hr before and 1 hr after SMA 
declamping) improved intermediate ( 16 and 
24 hr) survival, resulting in life table survival 
of these Group 5 rats that was nearly signif- 
icantly greater than saline treated Group 2 
rats, with P = 0.15 (Mantel-Cox). By 48 hr, 
however, the survival of Group 5 rats, treated 
with glucagon both during and after &hernia, 
was 33%, not significantly improved from 
the other treatment groups. 
To ensure that potential efficacy of gluca- 
gon treatment was not impeded by inadequate 
saline resuscitation, supplementary saline 
pretreatment was added to the glucagon- 
saline infusion previously shown to be nearly 
significant in Group 5 animals. In Group 6, 
saline was infused at 10 ml/kg/hr for 1 hr 
before glucagon treatment, beginning 35 min 
before ischemia, and in Group 7, twice this 
I I I 
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FIG. 3. Glucagon treatment (1.6 &kg/min) during 
(G-3) or after (G-4) ischemia did not improve survival 
over saline treated alone (G-2). Glucagon both during 
and after &hernia (G-5) nearly improved survival over 
saline alone (P = 0.15). 
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volume of supplementary saline was infused 
during the same interval. Neither of these 
groups demonstrated improved survival, 
however, either at 48 hr (33% in all Groups) 
or earlier, by life table analysis (Fig. 4). 
Next, the 2-hr glucagon-saline infusion 
(Group 5) that almost significantly improved 
survival when given during and after ischemia 
was delayed and given for 2 hr after ischemia 
(Group 9). This treatment resulted in a sig- 
nificant improvement of 48-hr survival, from 
33 to 83% (P < 0.02, x2) and a statistically 
significant improvement in life table survival 
(Group 9 vs Group 5, P < 0.02, Mantel- 
Cox, Fig. 5). As a control, saline infusion 
alone was given for 2 hr after ischemia, but 
did not improve early or 48-hr survival (33%, 
Group 8, Fig. 5). Glucagon-saline infusion 
for 2 hr after ischemia (Group 9) significantly 
improved survival compared with this saline 
control (Group 8) both at 48 hr (83% vs 
33%, P < 0.02, x2) and by life table analysis 
(P < 0.02, Mantel-Cox). 
Improved survival seen after postischemia 
glucagon infusion was dependent on adequate 
simultaneous saline replacement. When only 
1.5 instead of 10 ml/kg/hr of saline was 
administered with glucagon, 48-hr survival 
was reduced to 50% (8/16 rats, Group 10). 
This survival was intermediate to that seen 
with full-dose saline replacement (Group 9) 
and saline alone (Group 8, Fig. 6). By life 
table analysis, the survival for rats treated 
I I I I I I 
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FIG. 4. Saline preinfusion, before glucagon treatment, 
at 10 ml/kg/hr (G-6) or 20 ml/kg/hr (G-7), did not 
significantly improve survival compared to glucagon- 
saline treatment alone (G-S). 
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FIG. 5. Saline treatment for 120 min after &hernia 
(G-8) did not alter survival from saline treatment for 60 
min during and after &hernia (G-2). Glucagon treatment 
delayed until after ischemia (G-9), however, significantly 
improved survival compared with saline alone (G-8, P 
< 0.02) or glucagon during and after &hernia (G-5, P 
< 0.02). 
with glucagon and 1.5 ml/kg/hr of saline 
appeared better than rats treated with 10 ml/ 
kg/hr of saline alone (P = 0.024), but worse 
than rats treated with glucagon and 10 
ml/kg/hr of saline (Fig. 6, P = 0.065, 
Mantel-Cox). 
To further assess the value of glucagon 
infusion during occlusive mesenteric isch- 
emia, two additional treatment groups were 
compared. As a control, 12 rats received 
saline alone for 60 min during ischemia, 
followed by glucagon-saline treatment for 
120 min after ischemia (Group 11). This 
treatment resulted in the same 48-hr survival 
of 83% previously seen in rats treated with 
only postischemic glucagon-saline (Group 9). 
20- 
O I 
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FIG. 6. Glucagon plus saline at 10 ml/kg/hr for 120 
min after mesenteric ischemia (G-9) significantly im- 
proved survival over saline alone (G-8, P < 0.02). Glu- 
cagon plus 1.5 ml/kg/hr saline (G-10) produced an 
insignificant improvement in survival (G-8 vs G-10, P 
= 0.24; G-9 vs G-10, P = 0.065). 
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Glucagon-saline was then infused for 1 hr 
before and 2 hr after SMA declamping 
(Group 12). This additional hour of intra- 
ischemic glucagon treatment reduced 48-hr 
survival from 83% (Group 11) to 33% (4/12 
rats), equivalent to saline treatment alone. 
Life table survival of these groups was signif- 
icantly different (Fig. 7, P < 0.03, Mantel- 
Cox), as was the 33% vs 83% 48-hr survival 
(P < 0.02, x2). 
Autopsy of selected rats expiring prior to 
48 hr after mesenteric &hernia demonstrated 
patchy areas of full-thickness small bowel 
necrosis, with perforation and often frank 
purulent peritonitis. Light microscopy of these 
bowel segments demonstrated ischemic 
changes ranging from mucosal loss with acute 
inflammation in relatively preserved areas to 
full-thickness necrosis with hemorrhagic in- 
farction in advanced ischemia regions. Au- 
topsy of selected animals surviving more 
than 48 hr after ischemia demonstrated viable 
intestine with occasional areas of healing 
ischemic damage, manifested grossly by slight 
discoloration and microscopically by a 
chronic inflammatory infiltrate. 
DISCUSSION 
The rat mesenteric ischemia model used 
in this study was a severe one, resulting in 
100% mortality by 24 hr without treatment. 
Survival after temporary SMA occlusion is 
sensitive to the exact duration of ischemia, 
as well as other factors, such as extent of 
operative manipulation, catheter placement, 
etc. Pilot studies in our laboratory and a 
I 
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FIG. 7. Glucagon treatment during ischemia (G-12) 
significantly reduced survival when compared with effec- 
tive glucagon treatment after ischemia (G- 11, P i 0.03). 
detailed analysis of rat SMA occlusion times 
by Kazmers et al. resulted in the selection of 
85 min as an appropriate duration for isch- 
emia [9]. Despite the severity of this model, 
it was able to discriminate effective pharma- 
cologic treatment, as judged by the significant 
improvement in survival after postischemic 
glucagon-saline treatment. 
Adequate saline resuscitation was necessary 
for effective glucagon therapy in our study. 
Mesenteric &hernia is known to be associated 
with volume shifts from the intravascular 
compartment to the intestinal wall and lu- 
men, resulting in the potential for circulatory 
collapse upon vasodilator treatment [4, 121. 
The volume of saline resuscitation selected 
in our study, 10 ml/kg/hi-, represents vigorous 
replacement therapy and was superior to 
maintenance infusion of 1.5 ml/kg/hr of 
saline. Our study was not designed, however, 
to determine the optimal rate of saline re- 
placement, nor were measurements made of 
vascular volume in these rats. Therefore, in 
extrapolating these results to clinical therapy, 
vigorous saline replacement guided by appro- 
priate central monitoring should be applied, 
rather than any specific infusion guideline 
implied by these animal results. 
Comparison between Groups 11 and 12 
in our study demonstrates that glucagon in- 
fusion during occlusive ischemia was detri- 
mental if compared to infusion given only 
after ischemia. This inability of glucagon to 
improve survival when administered during 
occlusive ischemia was in sharp contrast to 
the marked improvement in survival seen 
when glucagon was withheld until after release 
of the SMA occlusion. These results support 
our previous study of canine intestinal blood 
flow measured during and after SMA tour- 
niquet ischemia [ 161. In that study, intrave- 
nous glucagon was not able to improve ileal 
wall flow during occlusive ischemia, and, in 
fact, reduced collateral blood flow as mea- 
sured by radiolabeled microspheres. After 
release of SMA occlusion in those dogs, 
however, glucagon markedly improved SMA 
blood flow and restored intestinal oxygen 
consumption to normal [ 161. 
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These results support the hypothesis that 
intravenous glucagon infusion during SMA 
occlusion is not capable of further vasodilat- 
ing ischemic areas of intestine that are already 
maximally vasodilated due to the local re- 
sponse to ischemia. In this situation, the 
ability of glucagon to vasodilate other (non- 
ischemic) splanchnic regions [ 141 could result 
in a detrimental redistribution of splanchnic 
blood flow, particularly if total flow is limited 
by reduced vascular volume or marginal car- 
diac reserve. After relief of occlusive SMA 
ischemia, however, local mesenteric vasodi- 
lation is replaced by a generalized vasocon- 
striction [2, 161. This vasoconstriction, in 
response to low cardiac output, has been 
attributed to diminished vascular volume, 
direct cardiac depressant substances, and 
other unknown factors [6, 11, 121. In the 
mesenteric circulation, it contributes to per- 
sistent intestinal ischemia and is therefore 
detrimental to the organism, assuming that 
adequate volume has been replaced to prevent 
cardiovascular collapse if vasodilation were 
to occur. In the present study, postocclusive 
glucagon treatment may have improved sur- 
vival by relieving ischemia that persists after 
release of SMA occlusion. 
The mechanism by which glucagon im- 
proved survival after mesenteric ischemia, 
however, was not specifically addressed in 
our study. Multiple factors may be involved 
in addition to the ability of glucagon to cause 
selective mesenteric vasodilation. Glucagon 
is known to provide cardiac inotropic and 
chronotropic support [ 10, 171. This may be 
important after mesenteric reperfusion, when 
cardiac depression is known to occur [4, 6, 
11, 161. Other glucagon actions, however, 
including its metabolic effects and inhibitory 
effects on gut and pancreatic secretion [ 131, 
may play a role in the effects of glucagon 
after mesenteric ischemia. Certainly, selective 
mesenteric vasodilation and cardiac inotropic 
support make glucagon an attractive agent 
for treatment of postocclusive mesenteric 
ischemia, as verified by the results of our 
study. The effectiveness of intravenously ad- 
ministered glucagon, as opposed to agents 
requiring selective SMA infusion [ 1, 31, adds 
to the potential of glucagon for clinical use. 
The results of our current study are at 
variance with the initial report of Kazmers 
et al. that glucagon infusion both during and 
after occlusive mesenteric ischemia improved 
rat survival [9]. This may relate to the larger 
volume of saline replacement (17 ml/kg/hr) 
used by Kazmers et al. to differences in the 
breed and size of rat employed, or to details 
of the experimental preparation. In the pres- 
ent study, where the timing of glucagon 
administration was specifically studied, there 
was clear evidence that optimal results were 
obtained by delaying this treatment until 
after the release of SMA occlusion. Caution 
must be exercised before generalizing this 
animal study to patient treatment, however, 
since mesenteric collateral blood flow, intes- 
tinal microcirculation, and systemic sympa- 
thetic and hormonal responses may differ in 
humans. Nevertheless, our study indicates 
that intravenous vasodilator therapy may not 
be beneficial during occlusive mesenteric 
ischemia, which should prompt further study 
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